U.S. pharma giant copyright scrapped two experimental weight loss drugs final yr—a the moment-every day capsule, lotiglipron, due to elevated liver enzymes plus a two times-each day tablet, danuglipron, as a result of solid Unwanted effects—but CEO Albert Bourla has reported the company is set to “play and win” while in the being overweight